BR112012023877A2 - dapsona aerossolizada como uma terapia para a inflamação das vias aéreas e transporte mucociliar anormal - Google Patents
dapsona aerossolizada como uma terapia para a inflamação das vias aéreas e transporte mucociliar anormalInfo
- Publication number
- BR112012023877A2 BR112012023877A2 BR112012023877A BR112012023877A BR112012023877A2 BR 112012023877 A2 BR112012023877 A2 BR 112012023877A2 BR 112012023877 A BR112012023877 A BR 112012023877A BR 112012023877 A BR112012023877 A BR 112012023877A BR 112012023877 A2 BR112012023877 A2 BR 112012023877A2
- Authority
- BR
- Brazil
- Prior art keywords
- dapsone
- therapy
- airway inflammation
- aerosolized
- mucociliary transport
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
dapsona aerossolizada como uma terapia para a inflamação das vias aéreas e transporte mucociliar anormal. dapsona aerossolizada (ou, alternativamente, uma formulação aquosa de dapsona) é usada para tratar inflamação das vias aéreas, particularmente, inflamação crônica dominada por neutrófilos. as doenças que podem ser prevenidas ou tratadas pelos métodos incluem doenças pulmonares obstrutivas crônicas (copds), asma, fibrose cística, entre outras.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31387710P | 2010-03-15 | 2010-03-15 | |
US41635310P | 2010-11-23 | 2010-11-23 | |
PCT/US2011/027494 WO2011115778A2 (en) | 2010-03-15 | 2011-03-08 | Aerosolized dapsone as a therapy for inflammation of the airway and abnormal mucociliary transport |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012023877A2 true BR112012023877A2 (pt) | 2016-08-02 |
Family
ID=44649767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012023877A BR112012023877A2 (pt) | 2010-03-15 | 2011-03-08 | dapsona aerossolizada como uma terapia para a inflamação das vias aéreas e transporte mucociliar anormal |
Country Status (8)
Country | Link |
---|---|
US (3) | US20130005822A1 (pt) |
EP (1) | EP2547335A4 (pt) |
JP (1) | JP5908884B2 (pt) |
KR (1) | KR101924162B1 (pt) |
AU (1) | AU2011227613B2 (pt) |
BR (1) | BR112012023877A2 (pt) |
CA (1) | CA2793170C (pt) |
WO (1) | WO2011115778A2 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6525203B2 (ja) | 2012-04-06 | 2019-06-05 | ザ ユーエイビー リサーチ ファウンデーションThe UAB Research Foundation | Cftr活性を増大させるための方法 |
JP6944701B2 (ja) * | 2016-10-21 | 2021-10-06 | 国立大学法人山口大学 | CD11bアンタゴニストを含む劇症型急性肺炎治療用組成物 |
CA3126367A1 (en) | 2020-03-30 | 2021-09-30 | Pulmonem Inc. | Dapsone formulations and methods of using same |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0617610T3 (da) | 1991-12-18 | 1997-10-06 | Minnesota Mining & Mfg | Suspensionsaerosolformuleringer. |
ATE236617T1 (de) | 1994-12-22 | 2003-04-15 | Astrazeneca Ab | Aerosol-arzneiformulierungen |
US20030082107A1 (en) * | 1997-10-01 | 2003-05-01 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
GB9820886D0 (en) | 1998-09-26 | 1998-11-18 | Glaxo Group Ltd | Inhalation device |
DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
JP2002543122A (ja) * | 1999-04-30 | 2002-12-17 | エイピーティー ファーマスーティカルズ エルエルスィー | 抗マラリア治療剤についての新規使用 |
CA2406383A1 (en) * | 2000-04-13 | 2001-10-25 | Mayo Foundation For Medical Education And Research | A.beta.42 lowering agents |
GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
US7077130B2 (en) | 2000-12-22 | 2006-07-18 | Chrysalis Technologies Incorporated | Disposable inhaler system |
US20030072737A1 (en) * | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
US7090830B2 (en) * | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
AUPS017702A0 (en) * | 2002-01-25 | 2002-02-14 | Atopic Pty Ltd | Methods and compositions for the treatment of asthma and related disorders |
EP1539284B1 (en) | 2002-09-06 | 2020-01-29 | Philip Morris Products S.a.s. | Aerosol generating device and method for generating aerosols |
US7497214B2 (en) | 2002-09-16 | 2009-03-03 | 3M Innovative Properties Company | Aerosol dispensers and adaptors therefor |
US7732134B2 (en) * | 2002-09-30 | 2010-06-08 | Novartis Ag | Methods to predict cholesterol elevation during immunosuppressant therapy |
US20040086469A1 (en) * | 2002-10-30 | 2004-05-06 | Osborne David W. | Protectant for UV-induced skin damage |
US7683029B2 (en) | 2003-05-07 | 2010-03-23 | Philip Morris Usa Inc. | Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin |
CN102060806A (zh) * | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
CA2542277A1 (en) * | 2003-10-21 | 2005-05-12 | Pharmacia Corporation | Method for the treatment or prevention of respiratory inflammation with a cyclooxygenase-2 inhibitor in combination with a phosphodiesterase 4 inhibitor and compositions therewith |
WO2007059905A2 (en) * | 2005-11-25 | 2007-05-31 | Develogen Aktiengesellschaft | Thienopyrimidines treating inflammatory diseases |
US20080066739A1 (en) * | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
US8586010B2 (en) * | 2008-02-27 | 2013-11-19 | Allergan, Inc. | Dapsone to treat rosascea |
WO2010099523A1 (en) * | 2009-02-27 | 2010-09-02 | University Of Cincinnati | Method of treating reactive airway disease |
-
2011
- 2011-03-08 US US13/583,434 patent/US20130005822A1/en not_active Abandoned
- 2011-03-08 JP JP2013500079A patent/JP5908884B2/ja active Active
- 2011-03-08 AU AU2011227613A patent/AU2011227613B2/en not_active Ceased
- 2011-03-08 BR BR112012023877A patent/BR112012023877A2/pt not_active IP Right Cessation
- 2011-03-08 EP EP11756734.7A patent/EP2547335A4/en not_active Withdrawn
- 2011-03-08 WO PCT/US2011/027494 patent/WO2011115778A2/en active Application Filing
- 2011-03-08 KR KR1020127026909A patent/KR101924162B1/ko active IP Right Grant
- 2011-03-08 CA CA2793170A patent/CA2793170C/en not_active Expired - Fee Related
-
2014
- 2014-10-22 US US14/520,976 patent/US20150040894A1/en not_active Abandoned
-
2018
- 2018-02-20 US US15/899,539 patent/US20180243213A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20130005822A1 (en) | 2013-01-03 |
US20180243213A1 (en) | 2018-08-30 |
AU2011227613A1 (en) | 2012-10-04 |
JP2013522295A (ja) | 2013-06-13 |
CA2793170A1 (en) | 2011-09-22 |
US20150040894A1 (en) | 2015-02-12 |
WO2011115778A2 (en) | 2011-09-22 |
KR20130055580A (ko) | 2013-05-28 |
KR101924162B1 (ko) | 2018-11-30 |
EP2547335A4 (en) | 2014-04-16 |
CA2793170C (en) | 2018-04-17 |
AU2011227613B2 (en) | 2015-09-03 |
JP5908884B2 (ja) | 2016-04-26 |
EP2547335A2 (en) | 2013-01-23 |
WO2011115778A9 (en) | 2012-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2013002542A1 (es) | Uso de una composicion farmaceutica inhalable que contiene glicopirrolato o una sal del mismo para el tratamiento o profilaxis de taquicardia en pacientes con enfermedad pulmonar obstructiva cronica, asma, fibrosis quistica y enfermedades relacionadas de las vias aereas. | |
PH12015501108B1 (en) | Treatment of pulmonary disease | |
ECSP13012978A (es) | Inhibidores de glucosilceramida sintasa | |
BR112017007072A2 (pt) | compostos de triazolopiridina e métodos para o tratamento de fibrose cística | |
BR112015006571A2 (pt) | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados | |
BR112015024869A2 (pt) | administração nasal | |
TN2015000091A1 (en) | Glucosylceramide synthase inhibitors | |
EP2749280A3 (en) | Combination of glycopyrronium and formoterol | |
BR112015003742A2 (pt) | sistema de montagem de componente de descarga | |
IN2014DN09326A (pt) | ||
CR20160327A (es) | (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
WO2012047674A3 (en) | Methods and compositions for disease treatment using inhalation | |
BR112013001119A2 (pt) | composição farmacêutica, processo para fabricar uma composição farmacêutica, uso de r(+)budesonida e um broncodilatador, e método de profilaxia ou tratamento de uma doença respiratória, inflamatória ou obstrutiva das vias aéreas | |
PE20121467A1 (es) | Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica | |
PE20141048A1 (es) | Combinacion que comprende umeclidinio y un corticosteroide | |
BR112017007138A2 (pt) | composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto. | |
BR112012004692B8 (pt) | solução que compreende levofloxacina para uso em um método para tratar a fibrose cística em um ser humano | |
BR112016015997A2 (pt) | ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas? | |
PE20150171A1 (es) | Nueva forma de dosificacion y formulacion de abediterol | |
BR112012023877A2 (pt) | dapsona aerossolizada como uma terapia para a inflamação das vias aéreas e transporte mucociliar anormal | |
ECSP11011323A (es) | Método o sistema que usa biomarcadores para el seguimiento de un tratamiento. | |
CL2008003495A1 (es) | Compuestos derivados de pirazol; composicion farmaceutica, metodo de preparacion y; su uso para tratar una enfermedad mediada por 5-lo tal como asma, broncocontriccion, enfisema, enfermedades obstructivas o inflamatorias de las vias respiratorias, bronquitis, lesion pulmonar aguda, bronquiectasia, rinitis alergica, entre otras. | |
BR112014005730A2 (pt) | método de tratar carcinoma mucoepidermóide | |
CL2014001046A1 (es) | Proceso de preparacion de compuestos derivados de acilguanidinas y aciltioureas, utiles para el tratamiento de enfermedades de los pulmones y de las vias respiratorias; y compuestos intermediarios utilizados en dicho proceso. | |
CL2015001729A1 (es) | Formulaciones líquidas que comprenden carbocisteína, al menos un agente regulador de ph, al menos un edulcorante y al menos un disolvente; y su uso para el tratamiento o la prevención de enfermedades del tracto respiratorio caracterizadas por producción de mucosidad excesiva y/o viscosa tales como gripe, otitis, epoc, bronquitis asmática y fibrosis quística. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A E 5A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |